Pacira Investor Day

Online Investor Kit

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

Date Documents

Recent SEC Filings

Filing date Form Description Filing Group Downloads
8-K

Report of unscheduled material events or corporate event

Current Reports
8-K

Report of unscheduled material events or corporate event

Current Reports
8-K

Report of unscheduled material events or corporate event

Current Reports
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5

Fact Sheets

There are currently no items available.

Recent Press Releases

Date Title and Summary
Toggle Summary Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings
Toggle Summary Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL
TAMPA, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it will host an Investor Day on Friday, October 15, 2021, from 8:00 AM to approximately
Toggle Summary Pacira BioSciences Notified of Abbreviated New Drug Application Filing for EXPAREL®
TAMPA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has received a Paragraph IV Certification Notice Letter advising that eVenus Pharmaceutical Laboratories,
Toggle Summary Pacira Announces Commercial Production Underway with Enhanced EXPAREL Manufacturing Process at Swindon Facility
Marks key step in achieving EXPAREL gross margins that exceed 85 percent by 2024 PARSIPPANY, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that
Toggle Summary Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries
Study demonstrating safety and tolerability of EXPAREL published in Journal of Clinical Anesthesia PARSIPPANY, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that full results of its Phase 3 PLAY study of EXPAREL® (bupivacaine liposome injectable
Toggle Summary Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021
-- Expanding EXPAREL utilization continues to drive growth with average daily sales at 109% of August 2020 -- -- More than nine million patients treated with EXPAREL as of August 2021 -- PARSIPPANY, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.
Toggle Summary Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
PARSIPPANY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the H.C. Wainwright 23 rd Annual Global Investment Conference at 7:00 AM ET on Monday, September 13, 2021. Pre-recorded audio of the virtual event can be accessed by
Toggle Summary Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021
-- EXPAREL momentum continues with July 2021 average daily sales at 117% of July 2020 -- PARSIPPANY, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported
Toggle Summary Pacira BioSciences to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference
PARSIPPANY, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Wedbush PacGrow Healthcare Virtual Conference at 10:20 AM ET on Tuesday, August 10, 2021. Live audio of the virtual event can be accessed by visiting the
Toggle Summary Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021
-- EXPAREL average daily sales at 178% of the prior year second quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative